Abstract Library

#4281 Automated (artificial intelligence) vs. manual evaluation of the somatostatin-receptor 2A and proliferation marker Ki-67 in neuroendocrine neoplasms: A pilot study

Introduction: Digital image analysis methods are currently being equipped with artificial intelligence (AI). Various AI applications are already in use to determine Ki-67. To date, there is no specialised AI application available to determine the somatostatin-receptor 2A (SSTR2A).

Conference:

Presenting Author:

Authors: Kaemmerer D, Lupp A, Klöppel G, Ayako I, Kasajima A,

Keywords: artificial intelligence, Ki-67, SSTR2A, usability, neuroendocrine neoplasm,

#3979 New insights into the progression of NET G3 with a focus of NETs with NEC-like transformation

Introduction: Despite increasing knowledge of the clinical and morphomolecular features of NETs G3, little is known about NETs showing NEC-like transformation. Recent studies reported that NETs G3 may share histological and genetic features with NECs, such as TP53 mutations.

Conference:

Presenting Author:

Authors: Kasajima A, Moser E, Pfarr N, Ito A, Vogel L,

Keywords: Neuroendocrine Tumor, Progression, Transition, NEC-like NET,

#3686 Clinical and morphogenetic features of renal neuroendocrine tumors

Introduction: Renal neuroendocrine tumors (RenNETs) are extremely rare.

Conference:

Presenting Author: Kasajima A

Authors: Kasajima A, Pfarr N, von Werder A, Schwamborn K, Esposito I,

Keywords: Renal NET, WHO classification, Histology, immunohistochemistry, NGS,

#3624 Clinical outcomes of everolimus (EVE) for patients with advanced rectal neuroendocrine tumors (ARNETs) – A single-institutional retrospective study

Introduction: RADIANT-4 has established EVE as one of the standard-of-care for advanced NET G1–2 of gastrointestinal or lung origin, with a trend of a poorer efficacy of EVE in ARNET (median progression-free survival [PFS] of EVE: 17.3 months in advanced midgut NETs vs 7.4 months in the ARNETs). Little is known about the clinical outcomes of EVE for ARNET G1–2 and G3 in the real-world setting.

Conference:

Presenting Author: Kim Y

Authors: Kim Y, Hirano H, Yamamoto S, Okita N, Shoji H,

Keywords: everolimus, rectal neuroendocrine tumor,

#3501 The dominant role of pancreatic and pulmonary NET G3 in a large consultation center series

Introduction: NETs G3 have been reported mostly in the pancreas, but other primary sites have not been well-investigated. Pulmonary atypical carcinoids corresponding to NET G3 were observed as metastases. Little is known about the progression of primary NETs to metastatic NET G3.

Conference:

Presenting Author: Kasajima A

Authors: Kasajima A, Konukiewitz B, Schlitter A, Weichert W, Klöppel G,

Keywords: Neuroendocrine Tumor G3, Prevalence, Origin, Metastasis, Development,